These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23104213)

  • 21. Predictive and prognostic markers in colorectal cancer.
    George B; Kopetz S
    Curr Oncol Rep; 2011 Jun; 13(3):206-15. PubMed ID: 21373987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
    Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
    J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
    Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F
    J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
    Barault L; Veyrie N; Jooste V; Lecorre D; Chapusot C; Ferraz JM; Lièvre A; Cortet M; Bouvier AM; Rat P; Roignot P; Faivre J; Laurent-Puig P; Piard F
    Int J Cancer; 2008 May; 122(10):2255-9. PubMed ID: 18224685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics.
    Levidou G; Saetta AA; Gigelou F; Karlou M; Papanastasiou P; Stamatelli A; Kavantzas N; Michalopoulos NV; Agrogiannis G; Patsouris E; Korkolopoulou P
    World J Surg Oncol; 2012 Feb; 10():47. PubMed ID: 22376079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pathologic diagnosis of colorectal cancer in the era of personalized therapy].
    Lai M
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):73-6. PubMed ID: 24742564
    [No Abstract]   [Full Text] [Related]  

  • 28. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
    Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
    Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine.
    Grothey A; Sargent DJ
    JAMA Oncol; 2016 Sep; 2(9):1133-4. PubMed ID: 27273467
    [No Abstract]   [Full Text] [Related]  

  • 30. Molecular markers predictive of chemotherapy response in colorectal cancer.
    Shiovitz S; Grady WM
    Curr Gastroenterol Rep; 2015 Feb; 17(2):431. PubMed ID: 25663616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA methylation predicts recurrence from resected stage III proximal colon cancer.
    Ahn JB; Chung WB; Maeda O; Shin SJ; Kim HS; Chung HC; Kim NK; Issa JP
    Cancer; 2011 May; 117(9):1847-54. PubMed ID: 21509761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B.
    Asaka S; Arai Y; Nishimura Y; Yamaguchi K; Ishikubo T; Yatsuoka T; Tanaka Y; Akagi K
    Carcinogenesis; 2009 Mar; 30(3):494-9. PubMed ID: 19147861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
    Chouhan H; Sammour T; Thomas ML; Moore JW
    J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers and efficacy: are we nearly there yet?
    Russo A; Rizzo S
    Ann Oncol; 2011 Jul; 22(7):1469-1470. PubMed ID: 21551003
    [No Abstract]   [Full Text] [Related]  

  • 36. Recent approaches to identifying biomarkers for high-risk stage II colon cancer.
    Akiyoshi T; Kobunai T; Watanabe T
    Surg Today; 2012 Nov; 42(11):1037-45. PubMed ID: 22961195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A correlation of the endoscopic characteristics of colonic laterally spreading tumours with genetic alterations.
    Metz AJ; Bourke MJ; Moss A; Dower A; Zarzour P; Hawkins NJ; Ward RL; Hesson LB
    Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):319-26. PubMed ID: 23354161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition?
    van Roon EH; van Puijenbroek M; Middeldorp A; van Eijk R; de Meijer EJ; Erasmus D; Wouters KA; van Engeland M; Oosting J; Hes FJ; Tops CM; van Wezel T; Boer JM; Morreau H
    BMC Cancer; 2010 May; 10():180. PubMed ID: 20444249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic relevance of occult metastases detected by cytokeratin 20 and mucin 2 mRNA levels in sentinel lymph nodes from colon cancer patients.
    Nordgård O; Oltedal S; Aasprong OG; Søreide JA; Søreide K; Tjensvoll K; Gilje B; Heikkilä R; Guriby M; Lothe RA; Smaaland R; Kørner H
    Ann Surg Oncol; 2012 Nov; 19(12):3719-26. PubMed ID: 22752373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.